Publication | Open Access

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)

Surgical OncologyNeoadjuvant Vinorelbine/epirubicinBreast OncologyMedicineCancer ManagementPharmacologyBreast CancerPharmacotherapyTopic 2Operable Breast CancerCancer TreatmentOncologyCancer Research